Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3391 | Problem-solving and relationship improvement intervention. Wiki | 0.71 |
drug1038 | Cognitive and behavioral intervention. Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D001997 | Bronchopulmonary Dysplasia NIH | 0.50 |
D006965 | Hyperplasia NIH | 0.50 |
D007239 | Infection NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19).
Description: Dose escalation of AT-100 will occur to determine the maximum dose (in mg) that produces no significant Dose Limiting Toxicities or dose-related Adverse Events (AEs).
Measure: Determining the highest-tolerated & safety-tested AT-100 dose Time: From time of initial AT-100 dosing until the end of the dosing period, up to 7 daysDescription: Days on mechanical ventilation.
Measure: Reduction in mechanical ventilation Time: From mechanical ventilation initiation up to Day 28Description: Incidence of death.
Measure: Mortality Time: Through study completion, up to Day 90The purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature at 36 weeks Postmenstrual Age (PMA), as compared to babies born premature who receive standard neonatal care alone.
Description: Dose escalation of AT-100 up to the maximum feasible dose in order to assess safety and tolerability
Measure: Phase 1b: Determining the highest-tolerated & safety-tested AT-100 dose Time: From time of initial AT-100 dosing until end of the dosing period, up to 7 daysDescription: Days on mechanical ventilation.
Measure: Phase 2: Reduction in time on mechanical ventilation Time: From birth to 36 Weeks Postmenstrual Age (PMA)Description: Incidence of BPD or death.
Measure: BPD or death Time: At 36 Weeks PMADescription: Days on mechanical ventilation.
Measure: Long term reduction in time on mechanical ventilation Time: From birth to 1 year Corrected Age (CA)Description: Days on respiratory oxygen support.
Measure: Long term reduction in time on respiratory support Time: From birth to 1 year Corrected Age (CA)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports